Andrew Namen, MD
Pulmonary Disease · Winston Salem, NCNPI 1518945872
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.6%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Inspire Medical Systems, Inc. accounts for 66.1% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $9,051, more than ten times the $826 reported in 2020.
Across 34 payments — averaging $482.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$11K
- Boehringer Ingelheim$5K
- Boehringer Ingelheim International GmbH$564
- Xeris Pharmaceuticals, Inc.$124
- Acera Surgical, Inc.$90
- Itamar Medical Inc$66
- plus $23 from 1 others
Across 25 payments — averaging $4087.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$102K
What the payments were for
- Consulting fees$8,14150%
- Speaking & faculty fees$4,44527%
- Travel & lodging$1,84111%
- Food & beverage$1,99312%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 14 | $10,845 |
| Boehringer Ingelheim | 14 | $4,707 |
| Boehringer Ingelheim International GmbH | 2 | $564 |
| Xeris Pharmaceuticals, Inc. | 1 | $124 |
| Acera Surgical, Inc. | 1 | $90 |
| Itamar Medical Inc | 1 | $66 |
| Philips North America LLC | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Inspire$8,944
- OFEV$5,062
- Inspire Upper Airway Stimulation System$1,578
- GVOKE HYPOPEN$124
How this compares
$16,420 in reported general payments places this provider in the 85th percentile of 393 pulmonary disease providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 99 | $1,329,636 |
| Sodium Oxybate | 12 | $228,593 |
| NucalaMepolizumab | 37 | $139,467 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 154 | $112,654 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 112 | $70,849 |
| Breo ElliptaFluticasone/Vilanterol | 120 | $63,662 |
| Spiriva RespimatTiotropium Bromide | 71 | $56,215 |
| Spiriva HandihalerTiotropium Bromide | 57 | $49,884 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 59 | $38,437 |
| Arnuity ElliptaFluticasone Furoate | 78 | $24,725 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 22 | $21,454 |
| Incruse ElliptaUmeclidinium Bromide | 38 | $17,366 |
| SymbicortBudesonide/Formoterol Fumarate | 55 | $17,074 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 23 | $14,049 |
| Pirfenidone | 13 | $11,887 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $4,707 | $1,470,750305 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 393 pulmonary disease providers in North Carolina.
Other pulmonary disease in Winston Salem
- Eugene BleeckerWinston Salem$357K
- Jill OharWinston Salem$226K
- Stephen PetersWinston Salem$59K
- Jessica FieldWinston Salem$55K
- Wendy MooreWinston Salem$48K
- Christina BellingerWinston Salem$32K
- Kapilkumar PatelWinston Salem$21K
- Chad MarionWinston Salem$17K
- Victor OrtegaWinston Salem$15K
- Michael PritchettPinehurst$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.